Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Poland
Poland- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
18 trials match your criteria
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Poland
Poland- Participants:18–64 years
Recruiting
InvestigationalNo placebo
Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis
InvestigationalNo placebo
- Disease:Dementia of the Alzheimer's type with delusions
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
- Disease:Dementia of the Alzheimer's type with delusions
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
Recruiting
Progressive multiple sclerosis
RecruitingInvestigational
Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis
Investigational
- Disease:Progressive multiple sclerosis
- Substances:Vidofludimus Calcium
Countries:Poland
Poland- Participants:18–64 years
- Substances:Vidofludimus Calcium
Recruiting
Relapsing multiple sclerosis+2
RecruitingRegistered drug
Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosisSecondary progressive multiple sclerosis+1
- Substances:TeriflunomideTolebrutinib+2
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Teriflunomide
Not recruiting
Migraine
Not recruitingInvestigational
Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments
Investigational
- Disease:Migraine
- Substances:Lu Ag09222
Countries:Poland
Poland- Participants:18–64 years
- Substances:Lu Ag09222
Not recruiting
Multiple sclerosis
Not recruitingRegistered drugNo placebo
Study Comparing CT-P53 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis
- Substances:MethylprednisoloneOcrelizumab+2
Countries:Poland
Poland- Participants:18–64 years
- Substances:Methylprednisolone
Not recruiting
Relapsing multiple sclerosis
Not recruitingRegistered drug
Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosis
- Substances:FenebrutinibTeriflunomide
Countries:Poland
Poland- Participants:18–64 years
- Substances:Fenebrutinib
Not recruiting
Multiple sclerosis
Not recruitingRegistered drug
Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis
Registered drug
- Disease:Multiple sclerosis
- Substances:–
Countries:Poland
Poland- Participants:18–64 years
Not recruiting
Multiple sclerosis
Not recruitingInvestigational
Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis
Investigational
- Disease:Multiple sclerosis
- Substances:Frexalimab
Countries:Poland
Poland- Participants:18–64 years
- Substances:Frexalimab
Not recruiting
Relapsing multiple sclerosis
Not recruitingRegistered drug
Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosis
- Substances:FenebrutinibTeriflunomide
Countries:Poland
Poland- Participants:18–64 years
- Substances:Fenebrutinib